KR100377280B1 - 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물 - Google Patents

디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물 Download PDF

Info

Publication number
KR100377280B1
KR100377280B1 KR1019950702950A KR19950702950A KR100377280B1 KR 100377280 B1 KR100377280 B1 KR 100377280B1 KR 1019950702950 A KR1019950702950 A KR 1019950702950A KR 19950702950 A KR19950702950 A KR 19950702950A KR 100377280 B1 KR100377280 B1 KR 100377280B1
Authority
KR
South Korea
Prior art keywords
hydrogen
pharmaceutical composition
group
compound
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019950702950A
Other languages
English (en)
Korean (ko)
Other versions
KR960700230A (ko
Inventor
사이피.순카라
쥴스프리드만
Original Assignee
메렐 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메렐 파마슈티칼스 인크. filed Critical 메렐 파마슈티칼스 인크.
Publication of KR960700230A publication Critical patent/KR960700230A/ko
Application granted granted Critical
Publication of KR100377280B1 publication Critical patent/KR100377280B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1019950702950A 1993-01-21 1993-12-17 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물 Expired - Fee Related KR100377280B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US656993A 1993-01-21 1993-01-21
US08/006569 1993-01-21

Publications (2)

Publication Number Publication Date
KR960700230A KR960700230A (ko) 1996-01-19
KR100377280B1 true KR100377280B1 (ko) 2003-07-18

Family

ID=21721516

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702950A Expired - Fee Related KR100377280B1 (ko) 1993-01-21 1993-12-17 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물

Country Status (20)

Country Link
US (1) US5648365A (enExample)
EP (1) EP0680470B1 (enExample)
JP (1) JP3398748B2 (enExample)
KR (1) KR100377280B1 (enExample)
AT (1) ATE150748T1 (enExample)
AU (1) AU679723B2 (enExample)
CA (1) CA2152794C (enExample)
DE (1) DE69309310T2 (enExample)
DK (1) DK0680470T3 (enExample)
ES (1) ES2102830T3 (enExample)
FI (1) FI112474B (enExample)
GR (1) GR3023188T3 (enExample)
HU (1) HUT72078A (enExample)
IL (1) IL108369A (enExample)
MX (1) MX9400563A (enExample)
NO (1) NO305166B1 (enExample)
NZ (1) NZ261414A (enExample)
TW (1) TW243445B (enExample)
WO (1) WO1994017040A1 (enExample)
ZA (1) ZA94317B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2129144C (en) * 1992-02-06 1999-07-13 Jules Freedman Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives
AU6366000A (en) * 1999-07-23 2001-02-13 Colorado State University Research Foundation Multidrug resistance pump inhibitors and uses thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
CA2465886A1 (en) * 2001-11-07 2003-05-15 Kathleen S. Crowley Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
KR100656490B1 (ko) 2001-11-26 2006-12-12 삼성에스디아이 주식회사 풀칼라 유기전계 발광표시소자 및 그의 제조방법
US8153184B2 (en) * 2001-11-26 2012-04-10 Samsung Mobile Display Co., Ltd. Organic EL display device and method of manufacturing the same
ES2831028T3 (es) 2013-02-08 2021-06-07 Gen Mills Inc Productos alimenticios reducidos en sodio
CN110372571B (zh) * 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1049377B (de) * 1952-04-03 1959-01-29 Abbott Laboratories, North Chicago, 111. (V. St. A.) Verfahren zur Herstellung von substituierten Vinylpiperidinen
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US3956296A (en) * 1974-12-11 1976-05-11 A. H. Robins Company, Incorporated 1-Substituted-4-benzylpiperidines
US4035372A (en) * 1976-08-13 1977-07-12 G. D. Searle & Co. 4-{[4-(Diphenylmethyl)-1-piperidinyl]methyl}benzenamines
EP0228893A3 (en) * 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US4990511A (en) * 1988-08-03 1991-02-05 Takeda Chemical Industries, Ltd. Amide compounds, their production and use
KR920702620A (ko) * 1989-06-19 1992-10-06 엠. 피. 잭슨 암치료에 유용하며 항히스타민성 특성을 갖는 약물
GB9000305D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Anticholinergic agents
EP0467435A3 (en) * 1990-07-19 1992-04-01 Akzo N.V. Benzhydryl derivatives having calmodulin inhibitor properties
DE69128820T2 (de) * 1990-08-14 1998-06-10 Hoechst Marion Roussel Inc Neue 19-Nor Steroide, die eine Amid tragende Gruppe in der 11-Beta-Stelle haben, ihre Herstellung, ihre Verwendung als Medikamente und pharmazeutische Präparate davon
CA2129144C (en) * 1992-02-06 1999-07-13 Jules Freedman Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives

Also Published As

Publication number Publication date
NZ261414A (en) 1997-06-24
JPH08505870A (ja) 1996-06-25
TW243445B (enExample) 1995-03-21
NO952885L (no) 1995-09-20
AU679723B2 (en) 1997-07-10
HU9502195D0 (en) 1995-09-28
DK0680470T3 (enExample) 1997-04-28
DE69309310D1 (de) 1997-04-30
EP0680470B1 (en) 1997-03-26
ZA94317B (en) 1994-08-18
ES2102830T3 (es) 1997-08-01
JP3398748B2 (ja) 2003-04-21
NO305166B1 (no) 1999-04-12
AU6014894A (en) 1994-08-15
KR960700230A (ko) 1996-01-19
FI953506A0 (fi) 1995-07-20
GR3023188T3 (en) 1997-07-30
FI953506L (fi) 1995-07-20
HUT72078A (en) 1996-03-28
IL108369A (en) 1999-08-17
NO952885D0 (no) 1995-07-20
US5648365A (en) 1997-07-15
DE69309310T2 (de) 1997-11-06
MX9400563A (es) 1994-07-29
EP0680470A1 (en) 1995-11-08
WO1994017040A1 (en) 1994-08-04
ATE150748T1 (de) 1997-04-15
FI112474B (fi) 2003-12-15
CA2152794A1 (en) 1994-08-04
CA2152794C (en) 1999-04-06
IL108369A0 (en) 1994-04-12

Similar Documents

Publication Publication Date Title
US7320991B2 (en) Analogs of thalidomide as potential angiogenesis inhibitors
US6921772B2 (en) Methods and compositions for the treatment of chronic lymphocytic leukemia
CZ157294A3 (en) Ndr reversible agents
KR100377280B1 (ko) 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물
JP2007536283A (ja) ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物
CA2129143C (en) Reversal of multi-drug resistance by tetraarylethylenes
WO2014116962A1 (en) Selective histone deacetylase 8 inhibitors
US5182293A (en) Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
CA2129144C (en) Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives
US5190957A (en) Treatment of multi-drug resistant tumors with quinolyl-and isoquinolyloxazole-2-ones
KR0168646B1 (ko) 피리디닐옥사졸-2-온의 다약제 내성 종양의 치료 용도
KR0168645B1 (ko) 퀴놀릴옥사졸-2-온 및 이소퀴놀릴옥사졸-2-온의 다약제 내성 종양의 치료 용도
US5670521A (en) Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives
TH63073A (th) อนุพันธ์อินโดลิลเพอริดีนในฐานะเป็นสารต้านฮิสทามีนและสารต้านภูมิแพ้
HK1099244A1 (en) Tetrahydroindolone derivatives for treatment of neurological conditions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060312

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060312